SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akari Therapeutics Plc (AKTX)

NEW YORK, May 12, 2017

The investigation concerns whether Akari and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On April 26, 2017, Edison Investment Research ("Edison") published a report, "Akari's Coversin matches Soliris in Phase II".  The next day, Edison renounced the report, mentioning the discovery of "material errors."  On May 11, 2017, Akari revealed that it had placed its Chief Executive Offer Gur Roshwalb on administrative leave pending investigation of the involvement of Akari personnel in the creation of the Edison report.  Following this news, Akari stock dropped $2.46 per share, or 21.41%, to close at $9.03 on May 12, 2017.

If you are aware of any facts relating to this investigation, or purchased shares of Akari, you can assist this investigation by visiting the firm's site: www.bgandg.com/aktx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com